Urupong
- Genmab A/S (GMAB) has been upgraded to Outperform at William Blair on numerous potential late-stage trial pipeline in 2026.
- William Blair analysts say that Johnson & Johnson (JNJ) opting out of growth of GEN3014 was unlucky, however largely
Source link
#Genmab #upgraded #Outperform #William #Blair #GMABNASDAQ
